| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Envoy Medical® Inc. (NASDAQ:COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced the issuance of U.S. Patent No. 12,465,754, granted by the United States Patent and Trademark Office (USPTO) on November 11, 2025.
The patent, titled "Combination Implant System with Removable Earplug Sensor and Implanted Battery," represents a significant addition to Envoy Medical's growing patent portfolio and reinforces the company's leadership in the fully implanted hearing device space. This new patent covers systems featuring an implantable subsystem that includes a stimulator and rechargeable energy storage, paired with a removable earplug that can receive electrical power from the implanted subsystem. The earplug includes a sensor and signal processor designed to generate stimulation signals and transmit them to the implantable subsystem.
This addition follows Envoy Medical's recent milestone achievements, including positive progress in its pivotal Acclaim® Cochlear Implant clinical trial, as the company continues to advance its mission of redefining hearing health through innovative, fully implanted solutions.
The Acclaim cochlear implant received Breakthrough Device Designation from the FDA in 2019 and is currently under investigation as part of a U.S. based pivotal clinical trial.
Posted In: COCH
